Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Articles online first > Giornale Italiano di Dermatologia e Venereologia 2020 Sep 17

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Giornale Italiano di Dermatologia e Venereologia 2020 Sep 17

DOI: 10.23736/S0392-0488.20.06514-1

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Pathogenesis of Smad7 in wound healing

Min-feng WU 1, Jian-hua HUANG 1, Qing-yu ZENG 2, Hong-wei WANG 1

1 Department of Dermatology, Huadong Hospital, Fudan University, Shanghai, China; 2 Shanghai Skin Disease Hospital, Institute of Photomedicine, Tongji University School of Medicine, Shanghai, China


PDF


Chronic refractory wounds are generally caused by local tissue defects and necrosis, and they are clinically characterized by difficult wound healing as well as high recurrence, which seriously affects the life quality of patients. However, specific medicine or acceptable therapeutics to treat these wounds are currently unavailable. Therapy primarily aims to accelerate generation of granulation tissue and decrease recurrence of wounds. The pathogenesis of chronic refractory wounds is closely related to multiple complex signaling pathways and a series of cytokines. Among these signaling pathways, the TGF-β/Smad7 axis plays a critical role in the course of this disease. Specifically, Smad7 is an antagonist of TGF-β that can inhibit activation of TGF-β. Moreover, Smad7 helps to promote wound healing by regulating related cytokines and controlling growth, differentiation and apoptosis of cells, which may be exploited to prevent and treat the disease. This review aims to reveal and evaluate the exact functions and mechanisms of Smad7 in regulation of wound healing.


KEY WORDS: Smad7; Wound healing; TGF-β; Pathogenesis

top of page